ZCCHC10 is a zinc finger protein that functions as a multi-faceted tumor suppressor across multiple cancer types. Primary Function: ZCCHC10 acts as a p53 stabilizer by binding p53 and disrupting its interaction with MDM2, thereby preventing MDM2-mediated p53 ubiquitination and degradation 1. Additionally, ZCCHC10 cooperates with the transcription factor PITX1 to suppress hTERT transcription, inhibiting telomerase-driven cellular immortalization 2. Mechanism: ZCCHC10 exerts tumor-suppressive effects through p53-dependent pathways, as its effects are absent in p53-null or p53-mutant cancer cells 1. The lncRNA SNHG1 epigenetically silences ZCCHC10 through recruitment of DNA methyltransferases (DNMT1/DNMT3B) to the ZCCHC10 promoter 3. miR-410-3p directly targets ZCCHC10 to activate NF-κB signaling, promoting epithelial-mesenchymal transition and cancer cell migration 4. Disease Relevance: ZCCHC10 expression is significantly downregulated in lung adenocarcinoma, colorectal cancer, melanoma, and acute myeloid leukemia tissues 1, 4, 2, 3. Clinical Significance: Decreased ZCCHC10 mRNA predicts poorer patient survival and correlates with cisplatin resistance in lung cancer 1 and venetoclax resistance in AML 3, positioning ZCCHC10 as a potential prognostic marker and therapeutic target.